Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow NKTR by emailGet an email when NKTR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NKTR, unsubscribe in one click. Privacy
📣 What NKTR Says Is Next
mid-2028 · “Importantly, our financial position is strong with over one billion dollars in cash and investments at the end of the quarter, and a cash runway that extends into the third quarter of 2028, past the initial Phase 3 data readouts expected in mid-2028.” Revenue in the second quarter of 2026 was $10.1 million as compared to $11.2 million in the second quarter of 2025.”
Company press release, Aug 13, 2026 · SEC filing
early 2027 · ““We initiated the first Phase 3 ZENITH AD trials in atopic dermatitis in July, and we plan to start a single registrational Phase 3 study in alopecia areata in early 2027.”
Company press release, Aug 13, 2026 · SEC filing
in 2027 · “Initial data expected in 2027 $3.6 B Scientific Rationale”
Company press release, Apr 20, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full NKTR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NKTR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.